Q-omics provides the consensus-scored HIF1A-AS3 profile across patient tissues and cancer cell-line models. HIF1A-AS3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, HIF1A-AS3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HIF1A-AS3 RNA expression shows 18,071 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where HIF1A-AS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIF1A-AS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIF1A-AS3 survival associations across molecular data types. HIF1A-AS3 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIF1A-AS3 RNA expression–survival associations across cancer types. High HIF1A-AS3 expression shows unfavorable associations in KICH, CESC, KIRP, UVM, STAD and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for HIF1A-AS3 RNA expression.
This table summarizes HIF1A-AS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HIF1A-AS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIF1A-AS3 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, KIRP, LUAD and BRCA. The KIRC box plot shows higher HIF1A-AS3 RNA expression in tumor versus normal tissue (log2 FC = +2.639, t-test p < 0.001).
This table shows molecular features associated with HIF1A-AS3 in patient tissues and cancer cell lines. In patient samples, HIF1A-AS3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
